<DOC>
	<DOCNO>NCT00179660</DOCNO>
	<brief_summary>To determine activity lenalidomide relapse refractory aggressive NHL .</brief_summary>
	<brief_title>Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Age great equal 18 year time signing informed consent form 3 . Able adhere study visit schedule protocol requirement 4 . Biopsyproven nonHodgkin 's lymphoma 5 . Aggressive lymphoma , follow histology acceptable : Follicular center lymphoma , grade 3 , Diffuse large cell , Mantle cell , Transformed 6 . Relapsed refractory previous therapy lymphoma . Patients must receive least one prior treatment regimen radiation , immunotherapy , chemotherapy , radioimmunotherapy , ineligible unwilling undergo autologous stem cell transplant . There limit number prior therapy . 7 . Patients must measurable disease cross sectional imaging least 2 cm long diameter . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 2 . 9 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study drug . 1 . Any following laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm^3 ( 1.5 x 10^9/L ) 2 . Platelet count &lt; 100,000/mm^3 ( 100 x 10^9/L ) 3 . Serum creatinine &gt; 2.5 mg/dL ( 221 mmol/L ) 4 . Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 5.0 x upper limit normal ( ULN ) 5 . Serum total bilirubin &gt; 2.0 mg/dL ( 34 mmol/L ) 2 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study 3 . All patient central nervous system ( CNS ) disease exception patient whose CNS disease treat chemotherapy , radiotherapy surgery remain asymptomatic , active CNS disease , show lumbar puncture , compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) , least 6 month . 4 . Prior history malignancy nonHodgkin 's lymphoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease &gt; equal 1 year 5 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form 6 . Known positive human immunodeficiency virus ( HIV ) 7 . Pregnant lactating female 8 . Prior &gt; equal grade 3 National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) allergic reaction/hypersensitivity thalidomide 9 . Prior &gt; equal grade 3 NCI CTCAE rash desquamating ( blister ) rash take thalidomide 10 . Prior use lenalidomide 11 . Use standard experimental anticancer drug therapy within 28 day day 1 study drug therapy 12 . Known active Hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>celgene</keyword>
	<keyword>cc-5013</keyword>
	<keyword>CC5013</keyword>
	<keyword>NHL</keyword>
	<keyword>Non-Hodgkins Lymphoma</keyword>
	<keyword>Revlimid</keyword>
</DOC>